Veru (NASDAQ:VERU) issued its earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05), MarketWatch Earnings reports. Veru had a negative return on equity of 52.81% and a negative net margin of 150.89%. The company had revenue of $5.20 million during the quarter, compared to analysts’ expectations of $7.25 million.
Shares of VERU opened at $1.35 on Friday. Veru has a one year low of $1.10 and a one year high of $2.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.01 and a quick ratio of 0.80.
Several brokerages have recently weighed in on VERU. HC Wainwright set a $5.00 target price on Veru and gave the stock a “buy” rating in a research report on Friday. Zacks Investment Research raised Veru from a “sell” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Wednesday, October 17th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of Veru in a research report on Monday, August 27th. Five research analysts have rated the stock with a buy rating, Veru has an average rating of “Buy” and a consensus price target of $5.50.
COPYRIGHT VIOLATION WARNING: “Veru (VERU) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2018/12/15/veru-veru-releases-quarterly-earnings-results-misses-expectations-by-0-05-eps.html.
Veru Company Profile
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
See Also: Different Types of Derivatives
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.